References



Acerca de RotaTeq
	¿Qué es RotaTeq?

	Informacíón sobre el estudio REST

	Eficacia

	Cobertura dirigida

	Perfil de seguridad

	Práctico y conveniente

	Información para prescribir

	Cómo administrar RotaTeq a los pacientes

Acerca de la Enfermedad
	Carga de la enfermedad y prevalencia

	Distribución por serotipos

	Signos y síntomas

Información adicional
	Novedades del rotavirus

	Sitios web afines

	Educación del paciente


1.	Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development of an effective rotavirus vaccine. Rev Med Virol. 2005;15:29–56.
2.	Datos en archivo, MSD México.
3.	Parashar UD, Bresee JS, Gentsch JR, Glass RI. Rotavirus. Emerg Infect Dis. 1998;4:561–570.
4.	Matson DO. Rotaviruses. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. Vol 2 2nd ed. New York, NY: Churchill Livingstone;2003:1106-1112.
5.	Raebel MA, ou BS. Rotavirus disease and its prevention in infants and children. Pharmacotherapy. 1999;19:1279–1295.
6.	Vesikari T, Matson DO, Dennehy P, y cols. Safety and efficacy of pentavalent human-bovine (W3C) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33.
7.	Glass RI, Parashar UD, Bresee JS, y cols. Rotavirus vaccines: current prospects and future challenges. Lancet. 2006;368:323–332.
8.	Glass RI, Bresee JS, Parashar UD, y cols. Rotavirus vaccines; past, present and future. Arch Pediatr. 2005;12:844–847.
9.	Velazquez FR, Matson DO, Calva JJ, y cols. Rotavirus infection in infants as a protection against subsequent infections. N Engl J Med. 1996;335:1022–1028.
10.	Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann. 2004;33:536–543.
11.	Bernstein DI, Ward RL. Rotaviruses. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 5th ed. Vol 2. Philadelphia, Pa: Saunders; 2004;4:2110–2133.
12. Van Damme P, Van der Wielen M, Ansaldi F, y cols. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis. 2006;6:805–812. 13. Velázquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis. 2000;182:1602–1609. 14. Van Damme P, Giaquinto C, Huet F, Gothefors L, Maxwell M, Van der Wielen M; for the REVEAL Study Group. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004–2005: The REVEAL Study. J Infect Dis. 2007;195(suppl 1):S4–S16. 15. Velázquez FR, Garcia-Lozano H, Rodriguez E, et al. Diarrhea morbidity and mortality in Mexican children: impact of rotavirus disease. Pediatr Infect Dis J. 2004;23(10 suppl):S149–S155.


	Imprimir

RotaTeq^® (vacuna oral pentavalente de virus vivos contra rotavirus) es una marca registrada de Merck & Co., Inc.